US-based Beauty Health Company’s core asset is HydraFacial, a patented skin treatment offered at beauty spas and clinics whose popularity has grown via social media with the hashtag hydraglow. The treatment costs around $200 a session and is recommended on a monthly basis. According to Meng, its “savvy” product design, much like the vacuum cleaner, is the first of its kind to show customers what has been extracted from their skin, creating ideal content for social media platforms.
“If there is anything we have learned in the last year and half we live in a Zoom and Instagram world where everyone wants to look good on camera,” she says.
The company’s serums, boosters and other tips used in treatment are said to be highly customizable and its ability to personalize treatment has helped the HydraFacial system “become more of a platform rather than a one trick pony that is vulnerable to fads,” the fund manager adds.
On RealSelf, which is said to be the definitive review website for medical treatments, HydraFacial has a 99 per cent “worth it” score which means that of the two thirds who try it for the first time they become repeat customers.
Meng is forecasting 30 per cent durable and organic growth driven by accelerating equipment placements and a price target of $40 a share for 40 per cent upside. While the company was growing at a 52 per cent revenue CAGR, or compound annual growth rate, it was still held up a 30 per cent during the pandemic.
“For a 30 per cent compounder we think that valuation is attractive for the growth,” she says. “The company (also) has $900m available for M&A deployment and given the track record of the management team and board we suspect that there will be a financially accretive announcement made in the near term.”
This article was originally posted by The Australian here.
Licensed by Copyright Agency. You must not copy this work without permission.
Eleanor Swanson of Firetrail Investments sat down with Equity Mates Media ahead of this year's conference. Eleanor shares the story of her first investment, breaks down the small cap landscape and shares some of the best companies that she's come across during her time in the markets.
.jpg)
Yen Liow of Aravt Global sat down with Equity Mates Media ahead of this year's conference. Yen shares the story of his first investment, Aravt's investment philosophy, his thoughts on the future of the payments industry and why he's excited to be a part of the Hearts & Minds family.
Hearts and Minds Investments Limited (ASX:HM1)'s Chief Investment Officer Rory Lucas and founding Hearts & Minds supporter Phil King of Regal Funds Management recently spoke with the hosts of You're In Good Company, an Equity Mates Media podcast. They discuss all things Hearts & Minds including the upcoming Conference, HM1 and what's involved as a Core and Conference Fund Manager. Phil also shares why he's proud to be part of the Hearts & Minds family, Regal's investment approach and explains what Alternative and Short investing is.
Warren Buffett’s right-hand man Charlie Munger is the headline act at Sohn Hearts and Minds this year and the 97-year-old investment legend is expected to offer forthright views on global financial markets which are now at a critical juncture.
.jpg)
.png)
